Over the past decade, neurodegenerative research and development has responsibly answered a foundational question: can we ...

Pfizer and Arvinas are poised to bring the third oral selective oestrogen receptor degrader (SERD) to market in the US, after ...

mRNA specialist BioNTech has chalked up an important win in its cancer pipeline, showing efficacy with its BNT111 vaccine candidate in a phase 2 trial in advanced melanoma. The study is looking at the ...

In another major setback for abortion care in the US, a US court has issued an order restricting the distribution of ...

Axsome Therapeutics' Auvelity has become the first non-antipsychotic therapy for agitation in patients with Alzheimer's ...

In its first meeting for months, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted against AstraZeneca's oral ...

Moderna saw its first-quarter revenues nearly triple to $389 million compared to the same period of 2025, with international ...

Regeneron has become the first company to get US approval for a gene therapy for congenital hearing loss, after the FDA gave ...

A court ruling in the US has delivered a setback for GSK and its Tesaro subsidiary in their dispute with AnaptysBio over ...

Avalyn Pharma has priced its initial public offering (IPO) on the Nasdaq, hoping to raise an upscaled $300 million for its ...

After a hiatus of almost a decade, Teva has made a pipeline-building acquisition, buying Emalex Biosciences and its candidate ...

In a statement, Prime Minister Keir Starmer said the "significant investment" had been "made possible by the pharmaceutical ...